Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

Stock futures are little changed after market returns to record highs: Live updates

August 12, 2025

Traders work at the New York Stock Exchange on August 12, 2025. NYSE Stock futures are little changed Tuesday night as investors look ahead to inflation data due later this week. Futures tied to the Dow Jones Industrial Average dropped 13 points, or less than 0.1%. S&P futures fell 0.04%, while Nasdaq 100 futures were […]

Do Kwon pleads guilty to U.S. fraud charges in billion crypto collapse

World

Do Kwon pleads guilty to U.S. fraud charges in $40 billion crypto collapse

August 12, 2025

Do Kwon, a South Korean cryptocurrency executive charged with fraud, stands with his attorney David Patton to plead guilty in front of U.S. District Judge Paul Engelmayer in New York City, New York, U.S., August 12, 2025 in this courtroom sketch. Jane Rosenberg | Reuters Do Kwon, the South Korean cryptocurrency entrepreneur behind two digital […]

World

China warns companies against using Nvidia and AMD chips, report says

August 12, 2025

Nvidia CEO Jensen Huang and U.S. Secretary of the Interior Doug Burgum attend the “Winning the AI Race” Summit in Washington D.C., U.S., July 23, 2025. Kent Nishimura | Reuters China has told companies to refrain from using Nvidia‘s H20 chips after the chipmaker recently received approval to resume shipping the less advanced artificial intelligence […]